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ABSTRACT 
Acute and chronic inflammatory lung diseases are often associated 
with epithelial cell injury/loss and fibroproliferative responses. 
ResolvinD1 (RvD1) is biosynthesized during the resolution phase of 
inflammatory response and exerts potent anti-inflammatory and 
promotes resolution of inflammatory lung diseases. The aim of this 
study was to investigate whether RvD1 exerts protective effects on 
alveolar epithelial cell function / differentiation and protects against 
fibroproliferative  stimuli. Primary human alveolar type II cells were 
used to model the effects of RvD1 in vitro upon wound repair, 
proliferation, apoptosis, transdifferentiation and epithelial 
mesenchymal transition (EMT). Effects of RvD1 upon primary 
human lung fibroblast proliferation, collagen production, and 
myofibroblast differentiation were also examined. RvD1 promoted 
alveolar type II (ATII) cell wound repair and proliferation. RvD1 
protected ATII cells against sFas-ligand/TNF-α -induced apoptosis 
and inhibition on cell proliferation and viability. RvD1 promoted ATII 
cells transdifferentiation. Moreover, we demonstrate that RvD1 
inhibited EMT in response to TGF-β. Furthermore RvD1 inhibited HLF 
proliferation, collagen production and myofibroblast differentiation 
induced by both TGF-β and bronchoalveolar lavage fluid (BALF) 
from ARDS patients. The effects of RvD1 were PI3-kinase 
dependent and mediated via  the resolvin receptor. RvD1 seems to 
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promote alveolar epithelial repair by stimulating ATII cells wound 
repair, proliferation, reducing apoptosis and inhibiting TGF-β 
induced EMT. While RvD1 reduced fibroproliferation, collagen 
production and myofibroblast differentiation. Together, these results 
suggest a potential new therapeutic strategy for preventing and 
treating chronic diseases (such as IPF) as well as the 
fibroproliferative phase of ARDS by targeting RvD1 actions that 
emphasizes natural resolution signalling pathways. 
Key words:  idiopathic pulmonary fibrosis, acute respiratory 
distress syndrome, resolvins, alveolar type II cells, lung fibroblast. 
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INTRODUCTION 
Chronic lung diseases such as idiopathic pulmonary fibrosis (IPF) 
are associated with loss of alveolar epithelial cells due to apoptosis, 
excessive fibroproliferation, aberrant deposition of extracellular 
matrix (EMC), inflammation and dysregulated repair of lung tissue.1, 
2 Many Studies suggest alveolar epithelial cells play a central role in 
the pathogenesis of IPF.3-6 In IPF, alveolar epithelial cells may 
undergo increased apoptosis through a Fas ligand–mediated 
pathway.7 Injury to the alveolar epithelial barrier is an early event 
during the development of pulmonary fibrosis.6 Timely repair of lung 
injury is essential for proper restoration of function. The repair of a 
damaged alveolar  epithelial barrier  is a complex  and poorly 
understood process that includes transdifferentiation of type II 
epithelial cells into type I epithelial cells, as well as regeneration of 
epithelial cells from stem cells.8 Dysregulation of  repair 
mechanisms such as epithelial to mesenchymal transition, may 
contribute to the generation of numerous ECM-producing 
fibroblasts/myofibroblasts,9, 10 that result in clinically significant 
pulmonary fibrosis. Similarly, in acute lung diseases such as acute 
respiratory distress syndrome (ARDS), the degree of the epithelial 
injury and the loss of alveolar epithelial cells due to Fas ligand–
mediated apoptosis is an important predictor of outcome.11-13 In 
some cases of ARDS, a marked fibroproliferative response is 
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associated with bad outcome.14 Therefore, a therapy that promotes 
epithelial repair and inhibits EMT could be useful in both acute and 
chronic respiratory disease, but only if it wasn’t also a stimulus for 
fibro-poliferation. 
  ResolvinD1 (RvD1) is a lipid mediator derived from both 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) which 
acts to dampen excessive PMN infiltration and transmigration.15 
Previous studies have suggested that RvD1 attenuates lung 
inflammation and can maintain the integrity of lung epithelium.16 
Furthermore, RvD1 has recently been shown to reduce interstitial 
fibrosis,17 inhibit cytokines release at sites of inflammation,18, 19 and 
is protective after ischemia-reperfusion second organ injury.17, 20 
RvD1 directly activates the lipoxinA4 receptor/formyl peptide 
receptor 2 (ALX/FPR2) with high affinity.21  
 Currently what is not known is whether RvD1 has a direct role in 
modulating human lung epithelial cell or primary human lung 
fibroblast proliferation and function.  
Our results indicate that  RvD1 promotes epithelial wound repair 
and inhibited TGF-β induced EMT in human adult type II alveolar 
epithelial cells, whilst inhibiting fibroproliferation and reducing the 
effects of TGF-β on primary human lung fibroblast (HLF) collagen 
production and myofibroblast differentiation. 
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MATERIAL AND METHODS  
Reviewers these are the short methods – more detailed 
methods are in the online supplement. 
Reagents 
ResolvinD1 was purchased from Cayman chemicals (Cayman 
Chemical Company, USA). Recombinant human TGF-β was 
purchased from R&D (R&D Sytems, Abingdon, UK). Antibody 
against caspase-8, AKT and phospho-AKT were obtained from Cell 
Signal Technology (Cell signal Technology, Boston, USA). Antibody 
against E-cadherin, N-cadherin and α -SMA were obtained from 
Abcam (Abcam, Cambridge, UK). Antibody against β-actin was 
purchased from Santa Cruz Biotechnology Inc (Santa Cruz, CA, 
USA). 
Primary lung cell culture 
ATII cells were isolated from peripheral normal lung tissue distal 
from the tumour in patients undergoing lung cancer resection. The 
cells were isolated in accordance with approval from the local 
research ethics committees at the University of Birmingham 
(Birmingham, UK). Primary human alveolar type II (AT II) cells 
were extracted according to methods described previously (see 
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online supplement).22 Average yields of primary human alveolar 
type II cells were 30.2 million cells per resection with an average 
purity of 92% ATII-like cells. Cells were tested for primary human 
alveolar type II  (AT II) cell phenotype by alkaline phosphatase 
staining, lysotracker lamellar body staining and by PCR expression 
of surfactant protein C—a type II cell marker with negative 
expression of aquaporin V (a type I cell marker) (data not shown).  
Primary human lung fibroblasts (HLF) from Lonza™ were similarly 
cultured in dulbecco modified Eagle medium culture media (ECACC, 
Sigma, Poole,UK)  supplemented with 10% FCS (sigma, Poole, UK) 
at 37 °C and 5% CO2. Cells were subcultured at 60-80% confluence 
using trypsin/EDTA. Cells were obtained from three separate donors, 
and all experiments were repeated in triplicate.  
Stimuli and Inhibitors.  ATII cells and fibroblasts were treated 
with resolvinD1 (10nM, 25nM or 100nM) (Cayman Chemical 
Company, USA). Appropriate vehicle controls were used for all 
experiments with inhibitors.  Inhibitors were used at the following 
concentrations according to manufacturers’ instructions: LY294002, 
a PI3-kinase inhibitor (Calbiochem, Nottingham, UK) at 10 µM; and 
the ALXR antagonist, Boc-2 (N-t-Boc-Phe-Leu-Phe-Leu-Phe; 
GenScript USA Inc), at 10µM. Inhibitors were added to cells 1 hour 
prior to every treatment. 
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Bronchoalveolar Lavage Fluid (BALF) Collection  
BALF from ARDS patients is known to stimulate epithelial repair in 
the scratch wound assay in an IL-1β dependent fashion.23 To test 
whether resolvin D1 could augment or synergise with this effect, the 
BALF from patients with ARDS were mixed 50:50 with appropriate 
culture media for each cell type as a positive control stimulus.  We 
used BALF from patients enrolled into the BALTI-1 trial, 
demographics for whom have been published previously.24 
In Vitro Alveolar Epithelial Wound Repair Assay. Epithelial 
repair was determined using an in vitro epithelial wound repair 
assay as described before.25 Briefly, primary human alveolar type II 
(AT II) cells were grown to confluent monolayers before wounding 
with a 1-mL pipette tip. Digital images of the same point on the 
wound were taken at time 0 and at time 36 hours. To control for the 
inconsistencies in wound size, only monolayers in which the original 
wound areas varied by 10% of the mean were analyzed. Repair is 
expressed as the percentage of the original wound area covered by 
cells relative to control media. To allow for variability between cell 
types and batches, data are expressed as the mean (SE) 
percentage of control).  
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BRDU cell proliferation assay and cell viability assays: BrdU 
incorporation was assessed according to manufacturers’ instructions 
(BRDU Cell Proliferation Assay, Promega, UK). Cell Viability after 24 
hours was assessed adding 20µL of Cell Titer 96 aqueous one 
solution cell proliferation solution (Promega, UK) to cells for 1.5 
hours at 37°C and 5% CO2 as described.26  
Flow Cytometry: Apoptosis of epithelial cells was assessed as 
described previously using flow cytometry.22 Cells were left in 
serum-free media for 24 hours before exposure to 100 ng/ml Fas-
ligand (R&D Sytems, Abingdon, UK). Apoptosis was determined by 
flow cytometry using the Annexin V and SyTOX antibody according 
to the manufacturer’s recommendations (Molecular Probes, Eugene, 
OR) after 24 hours exposure. 
Quantitative PCR:  Quantitative PCR was performed using 
commercially obtained primers as outlined in supplementary 
methods. 
Western Blot Analysis:  Western blot analyses from cells 
homogenates were performed as described previously. After equal 
amounts of protein were electrophoresed on 10/12% sodium 
dodecyl sulfate-polyacrylamide gels and then transferred to 
polyvinylidene difloride membranes (Millipore, Billerica MA01821). 
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Western blot analysis was performed using the Image Quant LAS 
4000 mini (GE).  
HLF proliferation assay in response to ARDS BALF: HLF were 
plated out at 2500 cells per well. A standard curve of cell counts 
was pipetted from 1250 to 15000 per well. BALF mixed 50:50 with 
media was added from 10 ARDS patients. After 24 hours BRDU 
incorporation was assessed according to manufacturers’ instructions 
(BRDU Cell Proliferation Assay, Promega, UK). Results were 
extrapolated from the standard curve.  Each patient sample was run 
with 6 replicates upon a single batch of HLF at passage 3. 
Statistical Analysis: Data were normally distributed and analyzed 
by analysis of variance with Tukey’s test for post hoc comparisons 
using Minitab 14.0 (Minitab, State College, PA).  A p value equal or 
less than 0.05 was considered significant. Data are expressed as 
mean (SEM).   
RESULTS 
ResolvinD1  stimulates  ATII cell wound repair and  
proliferation in vitro. 
RvD1 increased AT II cell wound closure after 36 hours compared 
with control media. ARDS BALF increased ATII cell wound closure 
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compared with media control23. RvD1 + ARDS BALF further 
enhanced the wound repair response (Fig. 1A). 
Scratch wound repair can occur due to either spreading of cells and 
/or proliferation. Cell proliferation studies confirmed that RvD1 
stimulated proliferation of AT II cell in a dose dependent manner 
(Fig. 1B).  
ResolvinD1 promotes ATII cell  proliferation through 
activation of ALX receptor and the PI3K/AKT signaling 
pathway.  
The PI3K/AKT signaling pathway plays an important role in cell 
proliferation. To determine if PI3-kinase signalling was involved in 
the RvD1 proliferative response, LY294002 (PI3K inhibitor) was 
incubated with ATII cells at 10 µM for 1 hour before RvD1 treatment 
of ATII cells. LY294002 treatment reversed the effects of RvD1 
(100nM) on the proliferation of ATII cells compared with control 
media–treated cells (Fig 2A). To investigate whether RvD1 can 
activate AKT phosphorylation in ATII cells, ATII cells were 
stimulated with different concentrations of RvD1 (10, 25, and 100 
nmol/ml) for 24h. We found that RvD1 activated AKT 
phosphorylation (Fig 2B). In addition, Pre-treatment of cells with 
Boc-2 (the resolvin ALX receptor antagonist) inhibited the effects of 
RvD1 on the proliferation of ATII cells (Fig. 2A). 
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ResolvinD1 protects against Fas-ligand (sFasL)and TNF-α 
actions on ATII cells.  
sFasL and  TNF-α inhibited cellular proliferation  compared with 
control media–treated cells. This effect was attenuated by 100nM 
RvD1 pretreatment (see online supplement Fig.s1A). The addition of 
100 ng/ml soluble Fas-ligand (sFasL) or 100 ng/ml TNF-α, as 
expected, significantly reduced cellular viability compared with 
control group. Co-treatment with 100nM RvD1 significantly 
increased cellular viability compared with sFasL (p<0.01) ( see 
online supplement Fig.s1B)- an effect that was also reduced by 
RvD1 rescue therapy added 30 mins after treatment with sFasL 
(data not shown). sFasL treatment of ATII cells (which are known to 
be resistant to apoptosis) increased the number of apoptotic cells 
from 3.29±0.11% in control cells to 10.34±0.33% (p=0.01). 
Rescue treatment with RvD1 reduced the number of apoptotic cells 
to 4.12±0.52% (p=0.01) (Fig. 3A).  
ResolvinD1 inhibited Fas-ligand- induced caspase-8 activation 
in ATII cells. 
To research the impact of RvD1 on Fas-ligand induced ATII cells 
apoptosis, we preliminarily detected the caspase-8 levels in vitro. 
ATII cells were treated with Fas-ligand or/and RvD1. The protein 
levels of caspase-8 were quantified and analyzed in the indicated 
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groups (Fig. 3B). Fas-ligand promoted caspase-8 activation. RvD1 
inhibited Fas-ligand induced caspase-8 activation in ATII cells. 
ResolvinD1 promotes Aquaporin 5 gene expression (a type I 
epithelial cell marker) whilst inhibiting surfactant protein C 
(SP-C, a type II epithelial cell marker)  gene expression  on 
ATII cells. 
Aquaporin 5 (AQP 5) is a membrane protein that mainly facilitates 
osmotic water transport.28 AQP5 may promote alveolar fluid 
clearance or maintain integrity of epithelial barrier.29 Roles of AQP5 
other than fluid transport have been explored in animal lung injury 
models, results from these studies show that lung injury is 
associated with down-regulation of AQP5 expression.30, 31 AQP5 
expression has been used as a type I epithelial cell marker. To 
observe the effect of RvD1 on AQP5 and SP-C gene expression, ATII 
cells were treated by RvD1 for 24 hours. RvD1 increased AQP5 gene 
expression (2.42±0.34 fold) relative to control group, p=0.001(Fig. 
4A). RvD1 induced AQP5 expression was blocked by BOC-2 (the 
ALXR antagonist) (Fig. 4A). In contrast, RvD1 down-regulated 
mRNA expression of SP-C suggesting that RvD1 may promote 
transdifferentiation of ATII cells into ATI like cells(Fig. 4B). 
ResolvinD1 inhibit TGF-ß induced EMT in Primary human 
alveolar type II cells 
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The epithelial-mesenchymal transition (EMT) of alveolar epithelial 
cells is a phenotype conversion, which is one of the main 
mechanisms of pulmonary firosis.32 The EMT process of epithelial 
cells is often stimulated with TGF-β.32 In our study, EMT was 
induced in ATII cells with TGF-ß treatment. TGF-ß treated ATII cells 
showed a mesenchymal morphology (fibroblast-like), and RvD1 
restored the epithelial morphology of the cells to a certain extent 
(Fig. 5A). RvD1 blocked the expression of mRNA of mesenchymal 
markers including N-cadherin, vimentin, type I collagen, S100A4, 
and α-SMA, while RvD1 restored the expression of mRNA of E-
cadherin (Fig.5B). The effects of RvD1 on the TGF-β-treated E-
cadherin, a-SMA, N-cadherin of ATII cells were confirmed by 
Western blot. (Fig.5C). 
To elucidate the mechanism involved in the effects of RvD1 on EMT, 
pre-treatment of cells with Boc-2 (the ALX receptor antagonist), 
inhibited the effects of RvD1 on EMT of ATII cells. TGF-β-induced N-
cadherin expression was suppressed by RvD1, and pre-treatment of 
cells with Boc-2 incapacitated the effects of RvD1 on N-cadherin 
expression (Fig. 6). Reduced expression of E-cadherin in TGF-β-
treated ATII cells was restored by RvD1, but pre-treatment of cells 
with Boc-2 abolished the effects of RvD1 (Fig. 6). 
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ResolvinD1 inhibits proliferation of Primary HLF Induced by 
TGF-ß and this effect  was PI3-Kinase dependent and 
blocked by BOC-2. 
Cell proliferation studies confirmed that 100 nM RvD1 inhibited 
proliferation of primary HLF Induced by TGF-ß. Cells were treated 
with TGF-ß for 24 h with or without preincubation with the PI3- 
kinase inhibitor  LY294002 (10µM) or BOC-2 (10µM). RvD1 inhibited 
the effects of TGF-ß on HLF proliferation, and these effects were 
blocked by both LY294002 and BOC-2 (Fig. 7). 
ResolvinD1 inhibits proliferation of primary HLF induced 
bronchoalveolar lavage fluid (BALF) from patients with ARDS. 
ARDS BALF has previously been shown to promote fibroblast 
proliferation in vitro.33 To model the in vivo stimulus for 
fibroproliferation in ARDS, HLF were treated with a 50:50 mix of  
BALF from  patients with ARDS. RvD1 inhibited ARDS BALF induced 
proliferation in HLF (Fig 8). 
ResolvinD1 reduces primary HLF collagen production and α-
smooth muscle actin (α-SMA)  induced by TGF-ß and BALF 
from  patients with ARDS. 
We investigated the mRNA expression of type I collagen, type IV 
collagen and α-SMA in HLF induced by TGF-ß 10ng/ml with 
quantitative PCR. Gene expression of type I collagen, type IV 
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collagen and α-SMA were increased in HLF induced by 24 hours of 
treatment with TGF-ß relative to control group. Treatment with 
RvD1 significantly inhibited gene expression of type I collagen, type 
IV collagen and α-SMA in HLF induced by TGF-ß compared to TGF-β 
group respectively (Table 1). We also investigated the effect of 
ARDS BALF upon type I collagen, type IV collagen and α-SMA mRNA 
expression. Gene expression  of type I collagen, type IV collagen 
and α-SMA were increased in HLF induced by ARDS BALF relative to 
control group (see table 1). RvD1 significantly inhibited gene 
expression of type I collagen, type IV collagen and α-SMA in HLF 
induced by by ARDS BALF (see Table 1). 
 
DISCUSSION 
Epithelial injury is one of the hallmarks of ARDS and fibrotic lung 
diseases.1, 34 Progressive pulmonary fibrosis occurs due to recurrent 
injury to AECs followed by aberrant repair/regeneration of epithelial 
barrier, persistence of activated fibroblasts, and alterations in 
extracellular matrix (ECM).1, 35 It has been suggested that 
resolvinD1 (RvD1) exerts potent anti-inflammatory and 
proresolution  effects, without causing immunosuppression. 
Furthermore, we previously reported that RvD1 improved alveolar 
fluid clearance, decreased pulmonary edema and maintained the 
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integrity of lung epithelia in LPS-induced murine lung injury.36 
Aspirin-triggered RvD1 also improved epithelial and endothelial 
barrier integrity in a murine model of hydrochloric acid-induced 
ALI.37 RvD1 promoted macrophage phagocytosis of zymosan and 
apoptotic PMNs signaling through the human ALX and GPR32 
receptors.21 Based on this background, our purpose was to evaluate 
whether RvD1 stimulated physical wound repair, promoted cellular 
proliferation, and inhibited apoptosis in ATII cells processes that are 
dysregulated repair in ARDS and fibrotic lung diseases.  
The restoration of the alveolar epithelial barrier is a critical aspect of 
alveolar repair,25 and our study clearly demonstrated that RvD1 
stimulated alveolar repair promoting physical wound closure by 
inducing proliferation of primary alveolar epithelial cells. The PI3K-
AKT signaling pathway regulates proliferation. Recombinant mouse 
osteopontin induces the proliferation of human bronchial smooth 
muscle cells via the PI3K/AKT signaling pathway. 38 Our study also 
showed that the mitogenic response of ATII cells to RvD1 is 
mediated through activation of ALX receptor and the PI3K/AKT 
signaling pathway.  
However, the precise role of RvD1 as modulators of apoptosis 
remains elusive and it is also unclear whether the effects relate to 
increasing lung epithelial survival. Previous studies reported that 
RvD1 can stimulate apoptosis of T cells and PMNs, while our study 
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demonstrated that RvD1 inhibited apoptosis in sFasL treated cells. 
One study has also indicated that RvD1 decreased apoptosis 
induced by ER stress in HepG2 cells.39 Our study demonstrates that 
RvD1 reduced cell death in response to sFasL and /or TNF-α even 
when given after the onset of injury and, therefore, may have 
potential as a rescue therapy post-injury. Furthermore, these 
effects seemed to relate to caspase-8 activation as caspase-8 levels 
were elevated in the sFasL treated cells, and RvD1 suppressed 
sFasL induced caspase-8 activation in ATII cells. 
The normal alveolar epithelium is composed of two types of cells 
(AT I and ATII). The repair of the epithelial barrier is believed to 
involve the transdifferentiation of type II cells into type I epithelial 
cells.8 The inability of type II AECs to transdifferentiate into type I 
AECs have also been observed in human lung fibrosis.40 Our study 
showed that RvD1 promoted gene expression of AQP5 (type I 
marker) in ATII cells via activation of ALX supporting a potential 
role for RvD1 in promoting fluid transport. while RvD1 reduced gene 
expression of surfactant protein C (type II markers) in ATII cells 
suggesting that it may promote transdifferentiation of ATII cells 
towards the ATI phenotype. Otherwise, recurrent alveolar epithelial 
cell (AEC) injury that leads to aberrant activation of AEC (such as 
epithelial to mesenchymal transition, EMT), producing fibroblasts 
and myofibroblasts.9, 10  
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Epithelial mesenchymal transition (EMT) has been increasingly 
proposed as one of the causative mechanisms of lung fibrosis.41, 42 
In this study, we demonstrated that RvD1 restored the epithelial 
morphology of the cells to a certain extent. Our results also 
revealed that RvD1 inhibited TGF-ß induced expression of the 
mesenchymal markers N-cadherin, vimentin, (FSP)-1 (also called 
S100A4), type I collagen and a-SMA (the mesenchymal cell markers) 
mRNA expression, while maintaining   the epithelial marker E-
cadherin (the epithelial cell marker) mRNA expression in ATII cells. 
Effects that were confirmed by Western blot. These results suggest 
that RvD1 may be a suppressor of TGF-β-induced EMT in ATII cells. 
These effects were inhibited by pre-treatment of ATII cells with Boc-
2 (the resolvin ALX receptor antagonist). The role of RvD1 on EMT 
has also been documented in A549 cells lung cancer cells.43  
Recent studies have indicated that 17(R)-RvD1 attenuated 
bleomycin-induced pulmonary fibrosis by promoting the resolution 
of neutrophilic inflammation in mice.44 Treatment with 17(R)-RvD1 
attenuated neutrophil alveolar infiltration, lung collagen content, 
and type I collagen mRNA expression, which was inhibited by an 
antagonist of ALX/FPR2 receptor.44  Resolvin D1 (RvD1) can 
suppress renal fibrosis in the obstructed kidney via inhibiting 
fibroblast proliferation and production of fibronectin and collagen 
I.45, 46 We therefore studied the effects of RvD1 upon primary HLF. 
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RvD1 inhibited TGF-β induced proliferation in primary HLF via 
activation of ALX/FPLR-1 and this effect was mediated through the 
PI3/Akt signalling pathway. 
It is established that TGF-β, as a potent inducer of fibroblast 
differentiation into myofibroblasts, can stimulate fibroblast 
proliferation and collagen production.47, 48 We therefore addressed 
the possibility that RvD1 may inhibit their differentiation into 
myofibroblasts. RvD1 significantly inhibited gene expression of type 
I collagen, type IV collagen and α-SMA (a reliable myofibroblast 
marker) in HLF induced by TGF-β. We also showed ARDS BALF 
stimulated the expression of markers of myofibroblast 
differentiation when incubated with normal HLF; an effect that was 
blocked by RvD1. Our data therefore suggests that RvD1 has 
differential effects upon ATII and HLF cells in vitro; both promoting 
epithelial repair and inhibiting TGF-β induced EMT whilst reducing 
fibroproliferation. This differential effect is potentially vitally 
important for RvD1 if used as a novel therapy in both acute and 
chronic inflammatory lung diseases such as ARDS and IPF. 
In summary, these data provide evidence for a new mechanism by 
which RvD1 may contribute to alveolar repair promoting physical 
wound closure by inducing proliferation of primary human ATII cells 
in vitro. RvD1 protected ATII cells from pro-apoptotic stimuli even 
when given after the initial injury. RvD1 increased the expression of 
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the type I marker, AQP5, with reduction in SP-C by ATII like cells, 
potentially promoting transdifferentiation. Moreover, RvD1 inhibited 
EMT in response to TGF-β.  Intriguingly RvD1 also inhibited HLF 
proliferation, collagen production and α-SMA expression induced by 
both TGF-β and ARDS BALF. The potential key role for RvD1 during 
primary human ATII cells  and  HLF in vitro is summarized in Fig. 9. 
Our next step is to determine whether RvD1 has a role in regulating 
repair and EMT in animals models.  
In conclusion, these results suggest a potential new therapeutic 
strategy for preventing and treating chronic diseases (such as IPF) 
as well as the fibroproliferative phase of ARDS by targeting RvD1 
actions that emphasizes natural resolution signaling pathways. 
Further experiments are necessary to understand the basic 
mechanism underlying the anti-fibrotic and anti- apoptotic effects of 
RvD1, which are currently under investigation. 
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Figure legends 
Figure 1 ResolvinD1  stimulates  ATII cells wound repair and  
proliferation in vitro. A: RvD1 at different concentrations was 
added to monolayers of ATII cells physically wounded with a 1-mL 
pipette tip. To allow for variability between cell batches, data are 
expressed as the mean (SE) percentage of the baseline wound size 
for each separate set of experiments for each culture condition. B: 
RvD1 stimulated the proliferation of primary human Alveolar Type II 
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cell (ATII cell). Values of >1 fold of control reflect increased 
proliferation. N=6 for each culture condition, repeated using cells 
from 3 donors. 
Figure 2 RvD1 promotes ATII cells  proliferation through 
activation of ALX receptor and the PI3K/AKT signaling 
pathway. A: 100 nM RvD1 promoted proliferation of ATII cells. 
Pretreatment with 10 µM LY294002, a phosphatidylinositol 3'-
kinase/Akt inhibitor inhibited the effects of resolvinD1 on ATII cells 
proliferation of suggesting that the pro-proliferation effects of 
resolvinD1 are PI3-kinase dependent. BOC-2, the ALX receptor 
antagonist, was re-incubated with primary human Alveolar Type II 
cells at 10 µM for 1 hour before resolvinD1 treatment of AT II cells. 
BOC-2 treatment inhibited the effects of resolvinD1 on the 
proliferation of primary human Alveolar Type II cells (ATII cells) 
suggesting that the promoting proliferation effects of resolvinD1 are 
ALX receptor dependent. B: To investigate whether RvD1 can 
activate AKT phosphorylation in ATII cells, ATII cells were 
stimulated with different concentrations of RvD1 (10, 25, and 100 
nmol/ml) for 24h. We found that RvD1 activated AKT 
phosphorylation in a dose-dependent manner. 
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Figure 3 Effect of RvD1 upon effects of soluble Fas ligand and 
TNF-alpha on apoptosis and caspase-8 activation .  A: Flow 
cytometry analysis of annexin-positive cells 24 hours after 
treatment with 100 ng/mL sFasL. Co-treatment with resolvinD1 at 
100 nM reduced annexin binding. sFasL treatment of ATII cells 
increased the number of apoptotic cells from 3.29±0.11% in control 
cells to 10.34±0.33% (p=0.01). Rescue treatment with RvD1 
reduced the number of apoptotic cells to 4.12±0.52% (p=0.01) B: 
RvD1 inhibited sFasL induced caspase-8 activation on ATII cells. 
Western blots showing caspase-8 protein in ATII cells treated with 
100 ng/mL sFasL or/and RvD1 at 100 nM for 24 h. Caspase-8 
protein was quantifid and analyzed in the indicated groups. 
**p<0.01 relative to control group, ##p<0.01 compared to FasL 
group. 
 
Figure 4 RvD1 up-regulates Aquaporin V and down-regulates 
SPC.  
To observe the effect of RvD1 on AQP5 and surfactant ptotein C 
gene expression, ATII cells were treated by resolvinD1 for 24 hours. 
A: Aquaporin5 gene expression: resolvinD1 only (2.42±0.34 fold) 
relative to control group, p=0.001. The effect that can be blocked 
by BOC-2 (the FPR antagonist) (resolvinD1+BOC-2, mean, 
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0.54±0.11 fold, p=0.001). B: Surfactant ptotein C gene expression: 
resolvinD1 only (0.54±0.05 fold) relative to control group, p=0.001. 
The effect that can be blocked by BOC-2 (the FPR antagonist) 
(resolvinD1+BOC-2, mean, 0.82±0.03 fold, p=0.01). 
Figure 5 ResolvinD1 inhibits TGF-ß induced EMT in Primary 
human alveolar type II cells 
A:TGF-ß treated ATII cells showed a mesenchymal morphology 
(fibroblast-like), and RvD1 restored the epithelial morphology of the 
cells to a certain extent. B: ATII cells were pre-treated with RvD1 
for 2 h. The cells were then cultured with TGF-ß (10 ng/ml) for 48h. 
ß-Actin was used here as an internal control. EMT was induced with 
TGF-ß treatment. TGF-ß treatment induced the expression of mRNA 
of mesenchymal markers including N-cadherin, vimentin, type I 
collagen, S100A4, and α -SMA, and reduced the expression of 
epithelial markers such as E-cadherin. RvD1 blocked the expression 
of mRNA of mesenchymal markers including N-cadherin, vimentin, 
type I collagen, S100A4, and α -SMA, while RvD1 restored the 
expression of mRNA of E-cadherin, **p<0.01 relative to control 
group respectively, ##p<0.01 compared to TGF-β group 
respectively.C: The effects of RvD1 on the TGF-β-treated E-
cadherin, a-SMA, N-cadherin of ATII cells were confirmed by 
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Western blot. **p<0.01 relative to control group respectively, 
##p<0.01 compared to TGF-β+ RvD1 group respectively. 
Figure 6 RvD1 inhibits TGF-β induced EMT in Primary human 
alveolar type II cells via ALX/FPR2 receptor.  
To elucidate the mechanism involved in the effects of RvD1 on EMT, 
pre-treatment of cells with Boc-2 (the ALX receptor antagonist), 
inhibited the effects of RvD1 on EMT of ATII cells. TGF-β-induced N-
cadherin expression was suppressed by RvD1, and pre-treatment of 
cells with Boc-2 incapacitated the effects of RvD1 on N-cadherin 
expression. Reduced expression of E-cadherin in TGF-β-treated ATII 
cells was restored by RvD1, but pre-treatment of cells with Boc-2 
abolished the effects of RvD1. **p<0.01 relative to control group 
respectively, ##p<0.01 compared to TGF-β+RvD1 group 
respectively, &&p<0.01 compared to TGF-β+RvD1 group 
respectively. 
 
Figure 7 Effect of RvD1 on primary HLF proliferation in response to 
TGF-ß 
Cell proliferation studies confirmed that resolvin D1 inhibited 
proliferation of primary HLF induced by TGF-ß. Cultured and serum-
deprived cells were treated with 10 ng/ml TGF-ß for 24 h with or 
without pre-incubation with LY294002 (10µM) for 1h, BOC-2 (10µM) 
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for 1 h. Data are mean ± SEM of three independent experiments. 
&<0.05, compared with no treatment group；**P < 0.01, compared 
with TGF-ß only group. 
Figure 8 Effect of RvD1 on primary human lung fibroblast 
(HLF) proliferation in response to acute respiratory distress 
syndrome (ARDS) bronchoalveolar lavage fluid (BALF).  
Bronchoalveolar lavage fluid (BALF) from patients with ARDS 
stimulated proliferation of primary HLF. Resolvin D1 inhibited the  
proliferation of primary HLF induced bronchoalveolar lavage fluid 
(BALF) from  patients with ARDS. Data are mean±SEM of three 
independent experiments. 
 
Figure 9 The key role for RvD1 during primary human ATII 
cells and  HLF in vitro 
Table 1 Summary of the different types gene expression in 
response to treatment of different stimulations 
 
 
 
